Arno Therapeutics (PK) Stock Price - ARNI

Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Arno Therapeutics Inc (PK) ARNI OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.003 0.00 0.00 0.00 0.003 16:15:24
Bid Price Ask Price Spread Spread % News
0.0017 0.0032 0.0015 46.88% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Arno Therapeutics (PK) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 148.05k 49.35M $ -11.51M - - 14.00M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
6.38k $ - 0.00% - -

more financials information »

Arno Therapeutics (PK) News

Loading Messages....

Latest ARNI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARNI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0030.0030.0030.0033,0000.000.0%
1 Month0.00180.0030.00170.001734849,5570.001266.67%
3 Months0.00170.00350.00170.001910423,9390.001376.47%
6 Months0.00150.00410.0010.002477451,4740.0015100.0%
1 Year0.00150.00410.0010.00242139,9760.0015100.0%
3 Years0.1090.120.00050.015444576,035-0.106-97.25%
5 Years0.671.150.00050.255060953,909-0.667-99.55%

Arno Therapeutics (PK) Description

Arno is a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics. The company has exclusive worldwide rights to three innovative clinical stage compounds with unique mechanisms of action that have the potential to be first-in-class products for the treatment of various forms of cancer, including both hematologic malignancies and solid tumors, and other life threatening diseases. The lead compound, onapristone, is an oral, anti-progestin currently in a Phase I/II clinical trial for patients with castration resistant prostate cancer.


Your Recent History
USOTC
ARNI
Arno Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.